ABOUT HASTEN BIOPHARMACEUTICAL CO., LTD

About Hasten

ROOTED IN CHINA, THINKING GLOBALLY

Scroll down

Hasten Biopharmaceutical Co., Ltd.(Hasten), which integrates R&D, production and commercialization and covers the whole industrial chain, was established in 2020. Hasten is jointly invested and established by CBC Group, Hefei Industry Investment Group and Feidong County, Hefei City. In April, 2023, Hasten received a US$315 million fundraising round co-led by CBC and Abu Dhabi sovereign wealth fund, Mubadala Investment Company, with participation from other institutional investors. Proceeds will be used to fund future acquisitions and business development of innovative pipeline assets.

We are committed to becoming a leader in the healthcare industry. We will work closely with our stakeholders such as relevant government institutions, medical and health professionals and industry partners to continuously drive the management ecosystem of chronic diseases & critical care related diseases, aiming to build a leading innovative medical and healthcare enterprise in China so as to benefit more patients and create social value.

6 offices & branches
8 countries and regions in Pan-Asia,
mainland China & Switzerland patients benefited
2 overseas wholly-owned subsidiaries
1 production base

CEO MESSAGE

Summer XIA - CEO of Hasten Biopharmaceutical Co., Ltd.

In short term after it started commercial operation, Hasten quickly owned the commercialization rights of 1 innovative drug which is under development and 7 originator drugs that are originally from global top 500 MNCs in China. In the future, Hasten Biopharma will continue to maintain a rapid development trend, follow the pulse of the times, rooted in China while looking at the world, through the "whole industry" and "globalization" layout, connecting the upstream and downstream industry chain, with a diversified approach to enrich our product portfolio and product pipeline, to achieve the goal of meeting the needs of healthcare professionals and patients, to create our own era of highlight.

With a well-established commercialization marketing network and professional marketing team, Hasten Biopharma is like a ship flying forward. We will strive to move forward in the blue ocean of health care by the ship of doctor-patient service, taking human health as the shore, innovation as the paddle, forging ahead as the sail.

OUR CULTURE

VISION

VISION

We are committed to becoming a leader in the healthcare industry that is trusted by customers, recognized by employees, and respected by society
MISSION

MISSION

Invest in science and talents,

continue to leverage

commercialization advantages,

provide high-quality medicines and

solutions that improve lives of people

and create social value.
VALUE

VALUE

Integrity

Agility

Innovation

Ownership
AMBITIONS

AMBITIONS

In the future, the unmet medical needs in the fields of chronic diseases and critical care related diseases will be growing and generate large marketing potentials.

Rooted in China with a global perspective, Hasten will connect the upstream and downstream industrial chains through the layout of "whole industry" and "globalization". We will enrich product structure and pipelines in diversified ways and rely on the broad medical and health platform and resources of CBC Group, as well as invest in science and talents to continuously leverage commercialization advantages.

We are committed to becoming a leader in the healthcare industry. We will work closely with our stakeholders such as relevant government institutions, medical and health professionals and industry partners to continuously drive the management ecosystem of chronic diseases & critical care related diseases, aiming to build a leading innovative medical and healthcare enterprise in China so as to benefit more patients and create social value.